Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jan;282(1):251-256.
doi: 10.1007/s00405-024-09021-0. Epub 2024 Oct 15.

Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps' patients treated with Dupilumab

Cecilia Rosso  1   2 , Eugenio De Corso  3 , Anastasia Urbanelli  4 , Gianluca Fadda  5 , Alberto Maria Saibene  6 , Francesco Ferella  7 , Camilla Spanu  8 , Carlotta Pipolo  6
Affiliations
Multicenter Study

Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps' patients treated with Dupilumab

Cecilia Rosso et al. Eur Arch Otorhinolaryngol. 2025 Jan.

Abstract

Purpose: The advent of biologic therapies, notably Dupilumab, has transformed therapeutic approaches to nasal polyposis. This retrospective multicentric study aimed to investigate weight changes in CRSwNP patients undergoing Dupilumab treatment and explore potential correlations with olfactory improvement.

Methods: Ninety-six patients with CRSwNP were followed for at least 12 months, with assessments including BMI (Body Mass Index), olfactory function, and disease severity.

Results: Significant increases in BMI and olfactory perception were observed after 1 year of Dupilumab treatment (p < .001). Subgroup analysis showed that patients with hyposmia and normosmia at T12 (1-year follow up) experienced significant weight gain (p < .001) alongside improved olfaction (both p < .001). Conversely, patients with anosmia after 1 year of therapy and also patients with stable or worsened olfaction did not show significant BMI changes (respectively p = .201 and p = .107).

Conclusion: While these findings suggest a correlation between olfactory improvement and weight gain/BMI, factors like improved nasal airflow and corticosteroid cessation under Dupilumab treatment may also influence weight in CRPwNP patients. The study highlights the need for further research to elucidate the causal relationship and long-term implications of Dupilumab-induced olfactory improvement on weight regulation.

Keywords: BMI; Biologics; Chronic rhinosinusitis with nasal polyps; Dupilumab; Hyposmia; Olfaction.

PubMed Disclaimer

Conflict of interest statement

Declaration. Conflicting Interests: Eugenio De Corso: Lecture fees and participations in experts board meeting of GSK, Novartis, Sanofi, Astrazeneca, Firma. Carlotta Pipolo: Lecture fees and participations in experts board meeting of GSK, Novartis, Sanofi, Astrazeneca, Firma and Deca. All other Authors declare that there is no conflict of interest.

References

    1. Bachert C, Han JK, Wagenmann M et al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 147(1):29–36. 10.1016/J.JACI.2020.11.013 - PubMed
    1. Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1–464. 10.4193/RHIN20.600 - PubMed
    1. Mullol J, Bachert C, Amin N et al (2022) Olfactory outcomes with Dupilumab in Chronic Rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 10(4):1086–1095e5. 10.1016/J.JAIP.2021.09.037 - PubMed
    1. Chung JH, Lee YJ, Kang TW et al (2015) Altered quality of Life and Psychological Health (SCL-90-R) in patients with chronic Rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol 124(8):663–670. 10.1177/0003489415576181 - PubMed
    1. Kohli P, Naik AN, Harruff EE, Nguyen SA, Schlosser RJ, Soler ZM (2017) The prevalence of olfactory dysfunction in chronic rhinosinusitis. Laryngoscope 127(2):309–320. 10.1002/LARY.26316 - PMC - PubMed

Publication types

MeSH terms

Substances